Patents Assigned to Baker Medical Research Institute
  • Patent number: 9765129
    Abstract: The present invention relates generally to a method of increasing lipid oxidation in a mammal and to agents useful for same. More particularly, the present invention relates to a method of increasing lipid oxidation in a mammal by administering a ligand which interacts with the IL-6 receptor and signals via interaction with a gp130/LIF receptor heterodimer. In a related aspect, the present invention provides a method of increasing insulin sensitivity in a mammal. The method of present invention is useful, inter alia, in the treatment and/or prophylaxis of conditions characterized by unwanted lipid accumulation (such as obesity, obesity induced-metabolic disorders, type II diabetes, dyslipidemia, glucose intolerance, insulin resistance, obstructive sleep apnea, cardiovascular disease or non-alcoholic fatty liver disease) or inadequate insulin sensitivity.
    Type: Grant
    Filed: August 16, 2013
    Date of Patent: September 19, 2017
    Assignees: Baker Medical Research Institute, Christian-Albrechts-Universität zu Kiel
    Inventors: Mark Anthony Febbraio, Stefan Rose-John
  • Publication number: 20140140949
    Abstract: The present invention relates generally to a method of increasing lipid oxidation in a mammal and to agents useful for same. More particularly, the present invention relates to a method of increasing lipid oxidation in a mammal by administering a ligand which interacts with the IL-6 receptor and signals via interaction with a gp130/LIF receptor heterodimer. In a related aspect, the present invention provides a method of increasing insulin sensitivity in a mammal. The method of present invention is useful, inter alia, in the treatment and/or prophylaxis of conditions characterised by unwanted lipid accumulation (such as obesity, obesity induced-metabolic disorders, type II diabetes, dyslipidemia, glucose intolerance, insulin resistance, obstructive sleep apnea, cardiovascular disease or non-alcoholic fatty liver disease) or inadequate insulin sensitivity.
    Type: Application
    Filed: August 16, 2013
    Publication date: May 22, 2014
    Applicants: Christian-Albrechts-Universität Zu Kiel, Baker Medical Research Institute
    Inventors: Mark Anthony Febbraio, Stefan Rose-John
  • Patent number: 7942927
    Abstract: A device (1) for treating valve failure in a patient is provided. The device has one or more engaging zones (3) for engaging the device with the annulus of the valve being treated. The device also has pre-disposition means for changing the geometry of the device to a predetermined configuration which is suitable for constricting the valve annulus. The device is compressible for percutaneous delivery to the valve. When in the predetermined configuration, the engaged device constricts the valve annulus facilitating substantial closure of leaflets of the valve.
    Type: Grant
    Filed: March 9, 2005
    Date of Patent: May 17, 2011
    Assignee: Baker Medical Research Institute
    Inventors: David Martin Kaye, John Melmouth Power, Clifton A. Alferness, Adam Lucas Bilney
  • Publication number: 20100278750
    Abstract: The present invention relates generally to branched macromolecules and their use as imaging or contrast agents. In particular, the invention relates to dendrimers, derived from lysine or lysine analogues, bearing a plurality of functional moieties and their application to imaging techniques in which a disease state may be imaged with a targeted contrast agent.
    Type: Application
    Filed: August 10, 2007
    Publication date: November 4, 2010
    Applicants: STARPHARMA PTY LTD, BAKER MEDICAL RESEARCH INSTITUTE
    Inventors: Guy Yeoman Krippner, Zemin Wu, Karlheinz Peter, Christoph Hagemeyer, David Owen
  • Publication number: 20090180960
    Abstract: Disclosed herein are compositions, methods, and kits for diagnosing or predicting a disease in a subject, for detecting activated platelets in a subject, and for treating a disease in a subject, wherein the diseases are mediated by platelet activation.
    Type: Application
    Filed: December 22, 2008
    Publication date: July 16, 2009
    Applicant: Baker Medical Research Institute
    Inventor: Karlheinz Peter
  • Publication number: 20090148383
    Abstract: The present invention provides an anticoagulant agent including a first element capable of inhibiting coagulation and a second element capable of targeting an activated platelet wherein upon administration of element directs the first element to the activated platelet. Also provided is a probe for detecting a blood vessel abnormality including (a) a binding element capable of targeting an activated platelet and (b) a label. Applicant has shown that agents and probes directed to activated platelets are useful in the diagnosis and therapy of coagulation disorders.
    Type: Application
    Filed: July 5, 2006
    Publication date: June 11, 2009
    Applicant: BAKER MEDICAL RESEARCH INSTITUTE
    Inventor: KarlHeinz Peter
  • Publication number: 20080288060
    Abstract: In a method of treating valvular insufficiency in a patient, a plurality of filaments (2) are used to engage tissue at spaced apart locations of an annulus (1) of the valve being treated. The engaged filaments (2) are drawn inward so as to draw the engaged tissue around the valve annulus (1) inward. The filaments (2) are then secured with the engaged tissue in the drawn-in configuration. Inward drawing of the engaged tissue improves valve function by reducing the valve annulus (1). Alternatively or additionally, anchor means may be used to secure the filaments to a region of robust tissue, thus drawing the engaged tissue toward the anchor means to further improve valve function.
    Type: Application
    Filed: July 6, 2005
    Publication date: November 20, 2008
    Applicant: Baker Medical Research Institute
    Inventors: David Martin Kaye, John Melmouth Power, Clifton A. Alferness, Adam Lucas Bilney, Mark L. Mathis
  • Publication number: 20080071364
    Abstract: A device (1) for treating valve failure in a patient is provided. The device has one or more engaging zones (3) for engaging the device with the annulus of the valve being treated. The device also has pre-disposition means for changing the geometry of the device to a predetermined configuration which is suitable for constricting the valve annulus. The device is compressible for percutaneous delivery to the valve. When in the predetermined configuration, the engaged device constricts the valve annulus facilitating substantial closure of leaflets of the valve.
    Type: Application
    Filed: March 9, 2005
    Publication date: March 20, 2008
    Applicant: BAKER MEDICAL RESEARCH INSTITUTE
    Inventors: David Martin Kaye, John Melmouth Power, Clifton A. Alferness, Adam Lucas Bilney
  • Publication number: 20070178086
    Abstract: The present invention provides a binding domain of ABCA1, wherein binding of a ligand to the domain is capable of modulating the biological activity of ABCA1. Also provided are methods for screening compounds capable of modulating ABCA1 activity, and antibodies useful in modulating ABCA1 activity.
    Type: Application
    Filed: November 27, 2006
    Publication date: August 2, 2007
    Applicant: Baker Medical Research Institute
    Inventors: Dmitri Sviridov, Nigora Mukhamedova, Ying Fu
  • Publication number: 20060264367
    Abstract: A method for treating cardiac fibrosis resulting from injury of a mammalian heart is described comprising the step of contacting a therapeutically effective amount of relaxin and/or an LGR7 activating agent with cardiac cells following the injury in an amount sufficient to reduce the fibrosis. Also described are methods for protecting the heart following an ischemic event, inhibiting the proliferation of activated fibroblasts and antagonising collagen secretion or deposition in a mammalian heart.
    Type: Application
    Filed: May 21, 2005
    Publication date: November 23, 2006
    Applicants: Howard Florey Institute, Baker Medical Research Institute
    Inventors: Chrishan Samuel, Ross Alexander Bathgate, Geoffrey Tregear, Xiao-Jun Du
  • Patent number: 5965372
    Abstract: The present invention relates generally to a nucleic acid molecule encoding, or complementary to a nucleic acid molecule encoding, a recombinant NAD+ dependent glucocorticoid dehydrogenase and more particularly to 11 .beta.-hydroxysteroid dehydrogenase-2 (11 .beta.HSD2). When expressed in a prokaryotic or eukaryotic cell, the nucleic acid molecule of the present invention is used to assay for potential agonists or antagonists of glucocorticoid dehydrogenase activity. Further, the present invention relates to immunoreactive molecules to NAD+ dependent glucocorticoid dehydrogenase which provide the basis for a new range of diagnostic agents for use, such as in the diagnosis and treatment of hypertension and in predicting the potential outcome of in vitro fertilisation and embryo transfer procedures.
    Type: Grant
    Filed: November 22, 1996
    Date of Patent: October 12, 1999
    Assignee: Baker Medical Research Institute
    Inventors: John W. Funder, Anthony L. Albiston, Varuni R. Obeyesekere, Zygmunt S. Krozowski, Robin E. Smith
  • Patent number: 5929039
    Abstract: The present invention relates generally to a method for, and pharmaceutical compositions useful in, the prophylaxis and/or treatment of cardiac dysfunction in a mammal by the administration of an effective amount of an agent capable of blocking or inhibiting the effect or release of inositol(1,4,5)trisphosphate in cardiac tissue.
    Type: Grant
    Filed: August 5, 1996
    Date of Patent: July 27, 1999
    Assignee: Baker Medical Research Institute
    Inventors: Elizabeth Anne Woodcock, Karen Elizabeth Anderson, Anthony Michael Dart, Xiao-Jun Du
  • Patent number: 5883240
    Abstract: The present invention relates generally to a nucleic acid molecule encoding, or complementary to a nucleic acid molecule encoding, a recombinant NAD+ dependent glucocorticoid dehydrogenase and more particularly to 11 .beta.-hydroxysteroid dehydrogenase-2 (11 .beta.HSD2). When expressed in a prokaryotic or eukaryotic cell, the nucleic acid molecule of the present invention is used to assay for potential agonists or antagonist of glucocorticoid dehydrogenase activity. Further, the present invention relates to inmmunoreactive molecules to NAD+ dependent glucocorticold dehydrogenase which provide the basis for a new range of diagnostic agents for use, such as in the diagnosis and treatment of hypertension and in predicting the potential outcome of in vitro fertilization and embryo transfer procedures.
    Type: Grant
    Filed: August 24, 1995
    Date of Patent: March 16, 1999
    Assignee: Baker Medical Research Institute
    Inventors: John W. Funder, Anthony L. Albiston, Varuni R. Obeyesekere, Zygmunt S. Krozowski, Robin E. Smith